Eptinezumab (Vyepti) Side Effects: What to Expect and Management

Eptinezumab-jjmr (Vyepti) is a CGRP antagonist administered IV quarterly for migraine prevention. Most side effects are mild and transient.

Common Side Effects (≥2% and >Placebo)

  • Injection Site Reactions: Pain, erythema, bruising, swelling, pruritus (typically mild, resolve in days).
  • Upper Respiratory Tract Infection: Nasopharyngitis, cold symptoms.
  • Headache/Migraine: Paradoxical worsening (rare; may reflect disease fluctuation).
  • Nasal Congestion, Pharyngitis, Cough

Less Common but Notable

  • Hypersensitivity reactions (rash, urticaria, angioedema, anaphylaxis — rare; observe post-infusion)
  • Fatigue, nausea, dizziness

Management

  • Pre-hydrate; slow infusion rate if reactions occur.
  • Topical cold compress, OTC antihistamine/analgesic for injection site symptoms.
  • Report persistent/severe symptoms to prescriber.
  • Pregnancy: Insufficient data; registry exists. Discuss risk/benefit.

Key Points

  • No laboratory monitoring required.
  • No hepatic/renal dose adjustment.
  • Can be used with acute migraine meds (triptans, gepants, NSAIDs).
  • Onset of prevention: some effect week 1; maximal by week 4.

Illness - Related Articles